JNB · SOL.JO
Sasol Limited
ZAR 289.84+ZAR 3.80 (+1.33%)
Sasol Limited’s quoted price sits in the upper half of its reported 52-week range, 3.57% below the high.
Loading market information…
JNB · ASC.JO · ZAc
Stock price, dividends, earnings
Quote as of Nov 28, 2025, 02:29 PM UTC. Cached market data; not a live quote.
One-year closing-price history · ZAc. Historical prices are not a forecast.
Ascendis Health Limited’s quoted price sits in the lower half of its reported 52-week range, 18.58% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Ascendis Health Limited’s forward annual dividend is ZAR 0.22 per share, paid semi-annual. The forward yield is 23.62% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Ascendis Health Limited’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Ascendis Health Limited is a health and wellness enterprise that manufactures and distributes healthcare products across South Africa, Cyprus, Spain, Hungary, Romania, and other international markets. The company's operations are divided into three key segments: Consumer Health, Pharma, and Medical. Within its Consumer Health portfolio, it offers a variety of body and skin care items, alongside numerous supplements such as natural, multi-vitamin, mineral, micronutrient, and nutraceutical options, as well as homeopathic and herbal remedies, marketed under brands like Bettaway, Chela-Fer, Chela Mag, Compounding Pharmacy, Junglevites, Menacal 7, Nimue, Scitec, Solal, and Vitaforce. The Medical segment provides essential medical devices, diagnostic laboratory equipment, and related consumables for diverse settings, including operating theatres, ICUs, trauma units, maternity and general wards, radiology, pathology labs, and scientific research institutes. Concurrently, the Pharma division offers a wide array of generic pharmaceutical products, encompassing antineoplastic agents, antivirals, aromatase inhibitors, anti-infectives, and treatments targeting the nervous and cardiovascular systems, dermatological issues, and antimalarial conditions, among other therapeutic solutions. These medical and pharmaceutical products are distributed under brands such as Pharmachem, Reuterina, Sinucon, Clonam, Phlexy, Surgical Innovations, RCA, and The Scientific Group. Ascendis Health also exports its products and serves a broad customer base including pharmacies, retailers, beauticians, and doctors. The company was founded in 2008 and is headquartered in Johannesburg, South Africa.
Latest available per-share figures in ZAR. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 10:33 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
ZAR 289.84+ZAR 3.80 (+1.33%)
Sasol Limited’s quoted price sits in the upper half of its reported 52-week range, 3.57% below the high.
ZAR 8.09+ZAR 0.01 (+0.12%)
PPC Ltd’s quoted price sits in the upper half of its reported 52-week range, 4.82% below the high.
ZAR 3.90ZAR 0.00 (0.0%)
Aveng Limited’s quoted price sits in the lower half of its reported 52-week range, 49.15% below the high.
